Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Cannon

Showing results (801-810 of 934) with videos related to

Pageof 94
Sort By:
Journal of the American College of Cardiology|January 30, 2016
Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT TrialSabina A Murphy, Christopher P Cannon, Michael A Blazing, et al.
The Journal of Biological Chemistry|July 26, 2002
The dual specificity JKAP specifically activates the c-Jun N-terminal kinase pathwayAlice J Chen, Guisheng Zhou, Todd Juan, et al.
Circulation|June 14, 2000
High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14S A Coulter, C P Cannon, K A Ault, et al.
Journal of the American College of Cardiology|October 29, 2013
Lipoprotein(a) for risk assessment in patients with established coronary artery diseaseMichelle L O'Donoghue, David A Morrow, Sotirios Tsimikas, et al.
Clinical Chemistry|November 5, 2016
Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart DiseaseEmil Hagström, Claes Held, Ralph A H Stewart, et al.
European Journal of Heart Failure|January 10, 2025
Heart failure outcomes captured by adverse event reporting in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trialAmbarish Pandey, Ahmed A Kolkailah, Darren K McGuire, et al.
Critical Pathways in Cardiology|August 31, 2010
Prior cardiovascular interventions are not associated with worsened clinical outcomes in patients with symptomatic atherothrombosisWilliam E Boden, Gregory S Cherr, Kim A Eagle, et al.
American Heart Journal|December 5, 2016
On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT)Michael A Blazing, Robert P Giugliano, James A de Lemos, et al.
Circulation. Cardiovascular Interventions|November 3, 2016
Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 UpdateDominick J Angiolillo, Shaun G Goodman, Deepak L Bhatt, et al.
Journal of the American College of Cardiology|October 2, 2012
Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgeryChristoph Varenhorst, Ulrica Alström, Benjamin M Scirica, et al.
Pageof 94

Showing results (801-810 of 934) with videos related to

Sort By:
Pageof 94
Journal of the American College of Cardiology|January 30, 2016
Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT TrialSabina A Murphy, Christopher P Cannon, Michael A Blazing, et al.
The Journal of Biological Chemistry|July 26, 2002
The dual specificity JKAP specifically activates the c-Jun N-terminal kinase pathwayAlice J Chen, Guisheng Zhou, Todd Juan, et al.
Circulation|June 14, 2000
High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14S A Coulter, C P Cannon, K A Ault, et al.
Journal of the American College of Cardiology|October 29, 2013
Lipoprotein(a) for risk assessment in patients with established coronary artery diseaseMichelle L O'Donoghue, David A Morrow, Sotirios Tsimikas, et al.
Clinical Chemistry|November 5, 2016
Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart DiseaseEmil Hagström, Claes Held, Ralph A H Stewart, et al.
European Journal of Heart Failure|January 10, 2025
Heart failure outcomes captured by adverse event reporting in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trialAmbarish Pandey, Ahmed A Kolkailah, Darren K McGuire, et al.
Critical Pathways in Cardiology|August 31, 2010
Prior cardiovascular interventions are not associated with worsened clinical outcomes in patients with symptomatic atherothrombosisWilliam E Boden, Gregory S Cherr, Kim A Eagle, et al.
American Heart Journal|December 5, 2016
On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT)Michael A Blazing, Robert P Giugliano, James A de Lemos, et al.
Circulation. Cardiovascular Interventions|November 3, 2016
Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 UpdateDominick J Angiolillo, Shaun G Goodman, Deepak L Bhatt, et al.
Journal of the American College of Cardiology|October 2, 2012
Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgeryChristoph Varenhorst, Ulrica Alström, Benjamin M Scirica, et al.
Pageof 94